Wire · operational-macro
Novo Gets FDA Approval For First-Of-Its-Kind Weekly Growth Hormone Treatment For ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
The FDA has approved Novo Nordisk's once-weekly growth hormone treatment, Sogroya, for children aged 2.5 and older with growth failure due to Turner syndrome. The treatment offers comparable growth to daily injections while significantly reducing the number of annual injections.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 20 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
You now have a new growth hormone treatment option for Turner syndrome that cuts injection frequency drastically. This shifts patient compliance and care models for paediatric rare diseases with hormone treatments.
◆ Coverage
2 sources · first reported 20 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics